Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...

Compass Pathways' COMP005 trial met its primary endpoint in TRD, but modest results sparked a 47% drop in shares amid ...

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in ...

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity ...

An Iowa lawmaker who had pushed for the passage Gov. Kim Reynolds’ decision to veto a bill pertaining to the psychoactive ...

Findings showed COMP360 psilocybin statistically significantly reduced symptom severity compared with placebo, as measured by MADRS.

Compass Pathways' psilocybin-based depression therapy reduced the severity of symptoms in a closely watched study, but shares of the biotech firm plunged more than 46% to a record low on Monday as the ...

The COMP360 program aims to evaluate the safety and efficacy of COMP360 psilocybin, a synthetic, proprietary formulation of psilocybin under investigation for difficult-to-treat mental health ...

A single administration of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS 1 with a mean difference of -3.6 ...